Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
entrez:
28
7
2021
pubmed:
29
7
2021
medline:
13
8
2021
Statut:
epublish
Résumé
It is unclear when, where, and by whom health care workers (HCWs) working in hospitals are infected with SARS-CoV-2. To determine how often and in what manner nosocomial SARS-CoV-2 infection occurs in HCW groups with varying exposure to patients with COVID-19. This cohort study comprised 4 weekly measurements of SARS-CoV-2-specific antibodies and collection of questionnaires from March 23 to June 25, 2020, combined with phylogenetic and epidemiologic transmission analyses at 2 university hospitals in the Netherlands. Included individuals were HCWs working in patient care for those with COVID-19, HCWs working in patient care for those without COVID-19, and HCWs not working in patient care. Data were analyzed from August through December 2020. Varying work-related exposure to patients infected with SARS-CoV-2. The cumulative incidence of and time to SARS-CoV-2 infection, defined as the presence of SARS-CoV-2-specific antibodies in blood samples, were measured. Among 801 HCWs, there were 439 HCWs working in patient care for those with COVID-19, 164 HCWs working in patient care for those without COVID-19, and 198 HCWs not working in patient care. There were 580 (72.4%) women, and the median (interquartile range) age was 36 (29-50) years. The incidence of SARS-CoV-2 was increased among HCWs working in patient care for those with COVID-19 (54 HCWs [13.2%; 95% CI, 9.9%-16.4%]) compared with HCWs working in patient care for those without COVID-19 (11 HCWs [6.7%; 95% CI, 2.8%-10.5%]; hazard ratio [HR], 2.25; 95% CI, 1.17-4.30) and HCWs not working in patient care (7 HCWs [3.6%; 95% CI, 0.9%-6.1%]; HR, 3.92; 95% CI, 1.79-8.62). Among HCWs caring for patients with COVID-19, SARS-CoV-2 cumulative incidence was increased among HCWs working on COVID-19 wards (32 of 134 HCWs [25.7%; 95% CI, 17.6%-33.1%]) compared with HCWs working on intensive care units (13 of 186 HCWs [7.1%; 95% CI, 3.3%-10.7%]; HR, 3.64; 95% CI, 1.91-6.94), and HCWs working in emergency departments (7 of 102 HCWs [8.0%; 95% CI, 2.5%-13.1%]; HR, 3.29; 95% CI, 1.52-7.14). Epidemiologic data combined with phylogenetic analyses on COVID-19 wards identified 3 potential HCW-to-HCW transmission clusters. No patient-to-HCW transmission clusters could be identified in transmission analyses. This study found that HCWs working on COVID-19 wards were at increased risk for nosocomial SARS-CoV-2 infection with an important role for HCW-to-HCW transmission. These findings suggest that infection among HCWs deserves more consideration in infection prevention practice.
Identifiants
pubmed: 34319354
pii: 2782430
doi: 10.1001/jamanetworkopen.2021.18554
pmc: PMC9437910
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2118554Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Nat Commun. 2020 Dec 11;11(1):6351
pubmed: 33311501
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Occup Environ Med. 2020 Dec 9;:
pubmed: 33298533
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
Anaesth Crit Care Pain Med. 2020 Oct;39(5):595-596
pubmed: 32861816
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
JAMA. 2020 Aug 4;324(5):441-442
pubmed: 32749495
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Antimicrob Resist Infect Control. 2021 Jan 6;10(1):7
pubmed: 33407833
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
Elife. 2020 Aug 21;9:
pubmed: 32820721
Cochrane Database Syst Rev. 2020 May 15;5:CD011621
pubmed: 32412096
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
BMJ. 2020 Oct 28;371:m3582
pubmed: 33115726
Virus Evol. 2019 Oct 09;5(2):vez039
pubmed: 31616568
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Am J Clin Pathol. 2020 Oct 13;154(5):592-595
pubmed: 32914176
J Hosp Infect. 2013 Nov;85(3):170-82
pubmed: 24051190
Lancet Infect Dis. 2021 Jan;21(1):23-24
pubmed: 32437699